PFE.BA - Pfizer Inc.

Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
516.80
0.00 (0.00%)
At close: 2:42PM ART
Stock chart is not supported by your current browser
Previous Close516.80
Open516.80
Bid517.00 x 0
Ask650.00 x 0
Day's Range516.80 - 516.80
52 Week Range282.70 - 516.80
Volume700
Avg. Volume78
Market Cap5.484T
Beta0.91
PE Ratio (TTM)143.60
EPS (TTM)3.60
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2015-02-04
1y Target EstN/A
  • MARKETS: Honeywell stock pops after raising full year guidance
    Yahoo Finance Video2 days ago

    MARKETS: Honeywell stock pops after raising full year guidance

    Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after Honeywell reported second quarter adjusted earnings per share and revenue that beat Wall Street Expectations.

  • TheStreet.comyesterday

    4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

    All four of these names have very strong cash flows that allow them to not only pay better than 3% dividends, but also to buy back stock. Two are consumer staples, a sector that's been the S&P 500's second-best performer over the past month (up 3.83%). The others are in health care, which has been the S&P 500's No. 3 best sector (+3%) during the past month.

  • See what the IHS Markit Score report has to say about Pfizer Inc.
    Markityesterday

    See what the IHS Markit Score report has to say about Pfizer Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. Over the last one-month, outflows of investor capital in ETFs holding PFE totaled $1.27 billion.

  • Pharmaceutical Companies Seek Stability in Trump Drug Cost Fight
    Bloomberg2 days ago

    Pharmaceutical Companies Seek Stability in Trump Drug Cost Fight

    Several major pharmaceutical companies lowered their spending on lobbyists in the second quarter of 2018, a time of uncertainty as President Donald Trump’s administration continued its campaign to lower drug costs for consumers. Pharmaceutical Research and Manufacturers of America spent $5.54 million between April and June, down 7.7 percent from the same period last year, according to disclosures released by the federal government on Friday. Companies including Johnson & Johnson and Bayer Corp. decreased their spending from the first quarter, when several companies set lobbying records amid the first signs of Trump’s moves to reduce out-of-pocket medicine costs.

  • MarketWatch2 days ago

    Pfizer gets FDA approval for drug similar to Amgen's Neupogen

    Pfizer Inc. (pfe) said late Friday it received Food and Drug Administration approval to sell a biotech drug that is similar to Amgen Inc.'s (amgn) Neupogen. Pfizer's product is named Nivestym, which is intended to reduce the likelihood of infections in cancer patients receiving chemotherapy. In a statement, Pfizer said it expects to sell Nivestym at "a significant discount to the current wholesale acquisition cost" of Neupogen.

  • Johnson & Johnson’s Revenues Came in ahead of Estimates in Q2
    Market Realist2 days ago

    Johnson & Johnson’s Revenues Came in ahead of Estimates in Q2

    Johnson & Johnson (JNJ) announced its Q2 2018 earnings results on July 17. JNJ stock rose ~3.5% on the day and ended at a closing price of $129.12. On July 16, the stock closed at $124.69.

  • TheStreet.com2 days ago

    GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

    American depository receipts surged on Friday, July 20, following a Financial Times report that the pharmaceutical giant's chairman Philip Roy Hampton is mulling a breakup of the firm. Hampton is considering a split-up after some of the company's large shareholders urged the board to think about spinning off the consumer unit, the report stated. The publication added that Hampton has talked to some shareholders about creating a standalone pharmaceutical and vaccines firm in the medium term.

  • Business Wire2 days ago

    U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)

    Pfizer Inc. (PFE) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NIVESTYM™ (filgrastim-aafi), a biosimilar to Neupogen1 (filgrastim), for all eligible indications of the reference product.

  • Barrons.com2 days ago

    [$$] Big Bet on Pfizer for a Market-Beating Investment Firm

    Returns for the firm’s largest fund, Jensen Quality Growth (JENSX), continue to top the S&P 500, including over the past 10 years through June 30. Other large second-quarter moves include taking large cuts to positions in Nike (NKE) and Mastercard (MA), and trimming back in Coca-Cola (KO) and Microsoft (MSFT). Jensen hasn’t yet responded to a request for comment.

  • Reuters2 days ago

    Swiss, German drugmakers join U.S. price freeze

    European drugmakers Roche , Bayer and Merck KGaA became the latest companies to freeze prices in the United States for the rest of 2018 following criticism by President Donald Trump over the cost of medicine. Roche did boost U.S. prices for nine key drugs by an average of 3 percent on July 1, but said it would hold off additional increases as discussions with the Trump administration continue over a longer-term solution to containing healthcare costs.

  • Roche Takes Drug-Price Posturing to New Heights
    Bloomberg2 days ago

    Roche Takes Drug-Price Posturing to New Heights

    Pfizer Inc. started things off earlier this month by agreeing to roll back mid-year price hikes and delay them — for a few months. Similar efforts announced this week by Novartis AG and Merck & Co. arguably won’t be any more consequential. In a statement Friday, the Swiss pharmaceutical giant said it told the Health and Human Services Department on July 11 that it wouldn’t enact any more price hikes in 2018.

  • Benzinga2 days ago

    Merck Announces Plans To Cut Drug Prices

    Last week, Pfizer Inc. (NYSE: PFE) announced plans to restructure the company and plans to deter price increases for as long as possible, assuming that Trump makes some changes. Merck announced Thursday that it will lower the price of several medications while also limiting future price increases. The price of several medications will drop by 10 percent, including Prinivil, Remeron and Trusopt, according to Merck.

  • Analysts’ Estimates and Recommendations for Allergan on July 19
    Market Realist2 days ago

    Analysts’ Estimates and Recommendations for Allergan on July 19

    Allergan’s stock price has fallen nearly 28.4% over the last 12 months, but it’s risen ~7.5% year-to-date in 2018. Analysts’ estimates show that the stock has the potential to return ~17.7% over the next 12 months.

  • Reuters2 days ago

    Swiss, German drugmakers join U.S. price freeze

    European drugmakers Roche (ROG.S), Bayer (BAYGn.DE) and Merck KGaA (MRCG.DE) became the latest companies to freeze prices in the United States following criticism by the Trump administration of the cost of medicine. Roche, Bayer and Merck KGaA all said on Friday they would not seek to lift prices this year in the world's biggest drug market, following Novartis (NOVN.S), Pfizer (PFE.N) and U.S. drugmaker Merck (MRK.N) which had already announced similar moves.

  • Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy
    Zacks2 days ago

    Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy

    Merck (MRK) announces a 60% cut in U.S. list prices for its hepatitis C drug, Zepatier. It will also lower the list price of some other drugs by 10%.

  • 3 Stocks That Could Be Added to the Dow Next
    Motley Fool2 days ago

    3 Stocks That Could Be Added to the Dow Next

    There have been over 50 component changes to the Dow's since 1896, and these three stocks could be the next to join the prestigious index.

  • Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals
    Zacks2 days ago

    Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

    J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.

  • TheStreet.com2 days ago

    Three Key Takeaways From Healthcare Earnings Season

    As the initial wave of healthcare companies unveil quarterly results, here are three takeaways from earnings calls. 1. Drugmakers are rethinking pricing strategies After Pfizer Inc. earlier this month said it would defer price hikes, Novartis AG said Wednesday, July 18, it will not raise prices for the rest of the year.

  • The Wall Street Journal3 days ago

    [$$] Merck to Limit Drug-Price Increases, Cut Some Prices

    Merck & Co. said Thursday it will cut U.S. list prices for several of its drugs including the hepatitis C treatment Zepatier, and the company pledged to limit future net price increases. Merck, based in Kenilworth, N.J., said it was cutting prices “to help reduce patient out-of-pocket costs.” The price cuts will go into effect in the fall, a spokeswoman said.

  • Reuters3 days ago

    Merck lowers prices of some drugs after Trump calls out industry

    Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers. Amid heightened political scrutiny over the high cost of prescription medicines and promises by Trump that drug price reductions were coming, New Jersey-based Merck became the first major drugmaker to announce voluntary price decreases. In addition to slashing the price of Zepatier, which owns a very small share of the hepatitis market, Merck said it would lower the list price by 10 percent of six other older drugs with minuscule sales.

  • How Celgene’s Abraxane and Otezla Are Positioned ahead of Q2 2018
    Market Realist3 days ago

    How Celgene’s Abraxane and Otezla Are Positioned ahead of Q2 2018

    Celgene’s (CELG) Abraxane reported revenue of $262 million in the first quarter, reflecting an ~11.0% YoY (year-over-year) rise. Abraxane’s sales grew 12.0% in the US market to reach $159.0 million. In the international market, its sales grew 9.6% to reach $103 million. Otezla and other drugs’ revenue trends

  • MarketWatch3 days ago

    AbbVie shares drop 5.5% after short seller Citron calls it 'next great drug short'

    AbbVie Inc. (ABBV) shares dropped 5.5% in heavy Thursday morning trade after short seller Citron Research described the company as "the next great drug short" in a tweet and said it planned to release reports about the company. The Citron tweet came the day after Food and Drug Administration Commissioner Scott Gottlieb put out a plan to encourage the development and uptake of lower-priced biosimilar drugs, accusing large drugmakers in a speech of stymying the competition. The short seller also predicted that AbbVie shares, which closed at $94.40 on Wednesday, would drop to $60.

  • Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study
    Zacks3 days ago

    Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study

    Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.

  • Better Buy: Novavax, Inc. vs. Pfizer
    Motley Fool3 days ago

    Better Buy: Novavax, Inc. vs. Pfizer

    Novavax and Pfizer have been chronic underachievers, but their stocks may soon perk up. Here's a look at which stock is the better buy right now.